Clinical review use long-acting somatostatin analog treatment gut neuroendocrine tumors SRIF analog octreotide SMS clinical use yr treatment acromegaly metastatic endocrine pancreatic carcinoid tumors use analog treatment acromegaly TSH-secreting tumors scope clinical review Patient acceptance analog sc route excellent side effects exception development gallstones endocrine pancreatic carcinoid tumors hypersecretion hormones VIP glucagon gastrin secretory products carcinoid tumors e.g tachykinins clinical effects excellent palliation tumors patients home lead normal social lives Initial hopes long-term octreotide therapy effective antitumor drug tumor growth experimental animal models human tumor cell lines clinical practice reduction gut tumor bulk due sustained phenomenon decrease absence clinical effectiveness reintroduction treatment modalities 